Research Profile: A/Prof Ian Seppelt
MB BS, BSc(Med), FANZCA, FJFICM
Department of Intensive Care Medicine
Nepean Hospital (University of Sydney)
University of Sydney
PO Box 63
Penrith NSW 2751
Senior Staff Specialist in Intensive Care Medicine, Nepean Hospital
Director of Clinical Research, Sydney West Area Health Service
Senior Research Fellow, The George Institute for International Health
Clinical Lecturer, Department of Medicine, University of Sydney
Secretary, ANZICS Clinical Trials Group and convenor of CTG Point Prevalence Program
Sedation and delirium in ICU. Projects include evaluations of both prevention and treatment of delirium in intensive care patients, quality of sedation, and specific work on the role of inhaled volatile anaesthetics for sedation in the ICU. Dr Seppelt is a member of a national Sedation Advisory Board for intensive care and co-chair of an ANZICS CTG Working Group on sedation and delirium research.
Pandemic influenza. Dr Seppelt is one of the lead investigators for the ANZ Intensive Care Influenza Registry and current projects include the epidemiology of critical illness in pregnancy, and the predictive value of ICU triage models in pandemics.
Management of traumatic brain injury. Dr Seppelt is a member of the Management Committee for DECRA, a prospective randomised controlled trial of early decompressive craniectomy in severe traumatic brain injury. Other studies include a prospective evaluation of the utility of brain oximetry in TBI using the LICOX and a clinical study of TBI metabolites and cytokines using microdialysis.
Quality and safety. Ongoing prospective evaluations of adverse events of intrahospital transport of intensive care patients and the use of non invasive ventilation in intensive care. Convenor of the Point Prevalence Program for the ANZICS Clinical Trials Group.
Management of shock in critical illness. Dr Seppelt was an investigator in the landmark SAFE, NICE and RENAL trials and has ongoing interests in fluid resuscitation, vasopressin and catecholamines in septic shock. He is national coordinator of the CRASH2 trial of tranexamic acid in traumatic haemorrhagic shock.